VEGFA and gastric cancer: Eligibility criteria for inclusion in this review were (i) histopathologically diagnosed gastric cancer, (ii) prospective phase II–III trials, (iii) involving adults patients aged 18 years and older, (iv) studies assessing the effect of anti-VEGF agents on patient’s outcomes in the management of advanced gastric cancer, (v) studies published in English.